Detalhe da pesquisa
1.
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Blood
; 141(22): 2738-2755, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36857629
2.
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
Blood
; 135(26): 2337-2353, 2020 06 25.
Artigo
Inglês
| MEDLINE | ID: mdl-32157296
3.
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.
Haematologica
; 107(2): 358-370, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34615339
4.
THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.
Int J Mol Sci
; 23(3)2022 Jan 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35163134
5.
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Cancer Sci
; 111(2): 561-570, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31782583
6.
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Blood
; 123(21): 3316-26, 2014 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-24705490
7.
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Proc Natl Acad Sci U S A
; 110(25): E2298-307, 2013 Jun 18.
Artigo
Inglês
| MEDLINE | ID: mdl-23737503
8.
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies.
Curr Hematol Malig Rep
; 17(6): 181-197, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36258106
9.
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
J Med Invest
; 67(3.4): 343-350, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33148913
10.
Heritable resistance to tyrosine kinase inhibitors.
Clin Adv Hematol Oncol
; 12(7): 454-7, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25322326
11.
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
Leukemia
; 33(8): 1835-1850, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31209280
12.
A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
Rinsho Ketsueki
; 54(10): 1714-9, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24064821
13.
Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches.
Sci Rep
; 8(1): 15028, 2018 10 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30301924
14.
The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.
PLoS One
; 13(10): e0205254, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30307989
15.
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
PLoS One
; 12(3): e0174107, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28301600
16.
Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Clin Cancer Res
; 23(12): 3139-3149, 2017 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27986747
17.
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia.
Leukemia
; 36(3): 892-896, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35121847
18.
Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.
Oncotarget
; 8(44): 77567-77585, 2017 Sep 29.
Artigo
Inglês
| MEDLINE | ID: mdl-29100409
19.
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
Oncotarget
; 8(25): 41474-41486, 2017 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28467813
20.
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Cancer Res
; 63(18): 5716-22, 2003 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-14522890